pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the Scottish Medicines Consortium (SMC) has accepted ILUVIEN® for use ...
pSivida has announced the availability of the sustained release pharmaceutical product indicated for the treatment of chronic diabetic macular edema (DME), Iluvien, in Germany. Alimera Sciences, pSivida's licensee, has reported the ...
Tags: pSivida Iluvien, Medicine
The Federal Ministry of Health of Germany has granted marketing authorization to pSivida for injectable, sustained-release intravitreal insert, Iluvien, designed as a treatment for vision impairment associated with chronic diabetic macular ...
Tags: Psivida, DME, clinical product
The US Food and Drug Administration (FDA) has approved pSivida's investigational new drug (IND) application for injectable sustained-release micro-insert, designed as a treatment for posterior uveitis. pSivida's injectable ...
The National Security Agency of Medicines and Health Products in France has granted marketing authorization to pSivida's ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME). The injectable, ...
UK-based Medicines and Healthcare products Regulatory Agency(MHRA)has granted marketing authorization to pSivida for its Iluvien insert. The marketing authorization follows the recently announced approval in Austria. The approvals were ...
Tags: pSivida Iluvien insert, MHRA, intravitreal insert, Iluvien
The Austrian Agency for Health and Food Safety has issued marketing authorization to pSivida ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME). The injectable, sustained-release ...
Tags: Marketing Authorization, reatment of vision impairment, clinical product